bioRxivCancer Biology
Identification of oncolytic vaccinia restriction factors in canine high-grade mammary tumor cells using single-cell transcriptomics
B. Cambien, K. Lebrigand, A. Baeri, N. Nottet, C. Compin, A. Lamit, O. Ferraris, C. Peyrefitte, V. Magnone, J. Henriques, L.-E. Zaragosi, S. Giorgetti-Peraldi, F. Bost, M. Gautier-Isola, R. Rezzonico, P. Barbry, R. Barthel, B. Mari, G. Vassaux
Abstract
Mammary carcinoma, including triple-negative breast carcinomas (TNBC) are tumor-types for which human and canine pathologies are closely related at the molecular level. Low-passage, primary carcinoma cells from TNBC versus non-TNBC were used to compare the efficacy of an oncolytic vaccinia virus (VV). We show that non-TNBC cells are 28 times more sensitive to VV than TNBC cells in which VV replication is impaired. Single-cell RNA-seq performed on two different TNBC cell samples infected or not with VV highlighted three distinct populations: naive cells, bystander cells, defined as cells exposed to the virus but not infected and infected cells. The transcriptome of these three populations showed striking variations in the modulation of pathways regulated by cytokines and growth factors. We hypothesized that the pool of genes expressed in the bystander populations was enriched in antiviral genes. Bio-informatic analysis suggested that the reduced activity of the virus was associated with a higher mesenchymal status of the cells. In addition, we demonstrate experimentally that high expression of one gene, DDIT4, is detrimental to VV production. Considering that DDIT4 is associated with a poor prognosis in various cancers including TNBC, out data highlight DDIT4 as a candidate resistance marker for oncolytic poxvirus therapy. This information could be used to design new generations of oncolytic poxviruses. Beyond the field of gene therapy, this study demonstrate that single-cell transcriptomics can be used to identify cellular factors influencing viral replication. Author summaryThe identification of cellular genes influencing viral replication/propagation have been studied using hypothesis-driven approaches and/or high-throughput RNA interference screens. In the present report, we propose a methodology based on single-cell transcriptomic. We have studied, in the context of oncolytic virothepary, the susc eptibility of primary, low-passage mammary carcinoma cells of canine origin from different grades to an oncolytic vaccinia virus (VV). We highlight a fault in replication of VV in cells originated from high-grade triple-negative breast carcinomas (TNBC). Single-cell RNA-seq performed on TNBC cell samples infected with VV suggested that the reduced activity of the virus was associated with a higher mesenchymal status of the cells. We also demonstrate that high expression of one gene, DDIT4, is detrimental to VV production. Considering that DDIT4 is associated with a poor prognosis in various cancers including TNBC, out data highlight DDIT4 as a candidate resistance marker for oncolytic poxvirus therapy. Beyond the field of cancer gene therapy, we demonstrate here that single-cell transcriptomics increases the arsenal of tools available to identify cellular factors influencing viral replication.
- assay: scRNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: gene regulatory network inference
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Non-canonical cell death by reassortant reovirus
R. M. Rodriguez Stewart, V. Raghuram, … B. A. Mainou·bioRxiv·May 20, 2020
- Vinorelbine enhances the efficacy of GM-CSF-armed oncolytic vaccinia virus in a preclinical model of ovarian high grade serous carcinoma
Stefania Drymiotou, Christophe J. Queval, … Michael Way·bioRxiv·Feb 4, 2025
- Oncolytic vaccinia virus expression of a defined peptide-MHCI complex as a precision cancer immunotherapy platform
Shae J Komant, Jun Li Wang, … Troy A. Baldwin·bioRxiv·Aug 16, 2024
- Recombinant measles virus equipped with BNiP3, a pro-apoptotic gene, targets β-catenin pathway in triple negative breast cancer cells
Alok Kumar, Kamaldeep, … Maitreyi S. Rajala·bioRxiv·Apr 18, 2026
- Receptor-guided engineering of oncolytic vaccinia creates a synthetic support niche for off-the-shelf NK cell therapy
Reza Rezaei, Zhiyang Gan, … Neil C. Sheppard·bioRxiv·Nov 9, 2026
- The anti-virus T cell response dominates the anti-cancer response in oncolytic virus therapy
Meghan J. O’Melia, Kailan Sierra-Davidson, … Sonia Cohen·bioRxiv·Sep 22, 2025